Mercer Global Advisors’s Niagen Bioscience NAGE Stock Holding History

Mercer Global Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$102K	Sell	31,862 -9,104	-22%	-$36.9K	﹤0.01%	3419
2026 Q1	$181K	Buy	40,966 +16,412	+67%	+$88.6K	﹤0.01%	2875
2025 Q4	$156K	Buy	24,554 +831	+4%	+$5.78K	﹤0.01%	2635
2025 Q3	$221K	Buy	23,723 +3,000	+14%	+$30.3K	﹤0.01%	2316
2025 Q2	$299K	Buy	20,723 +2,583	+14%	+$25.5K	﹤0.01%	1851
2025 Q1	$125K	Buy	18,140 +8,140	+81%	+$51.1K	﹤0.01%	2033
2024 Q4	$53K	Buy	+10,000	New	+$54.7K	﹤0.01%	2081
2024 Q2	–	Sell	-10,000	Closed	-$35K	–	2057
2024 Q1	$35K	Buy	+10,000	New	+$18.5K	﹤0.01%	1907
2023 Q4	–	Sell	-10,000	Closed	-$15K	–	2102
2023 Q3	$15K	Buy	+10,000	New	+$15.6K	﹤0.01%	1934

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mercer Global Advisors's NAGE Position: Q2 2026 in Review

Mercer Global Advisors reduced its Niagen Bioscience (NAGE) stake by 22% in Q2 2026, selling an estimated $36.9K and leaving 31,862 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #3419.

Mercer Global Advisors first reported a position in NAGE in Q3 2023 and has held it in 9 quarters since. The position peaked at $299K in Q2 2025. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

Mercer Global Advisors held 31,862 shares of Niagen Bioscience worth $102K as of Q2 2026.
Mercer Global Advisors sold 9,104 Niagen Bioscience shares in Q2 2026, an estimated $36.9K.
Niagen Bioscience made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3419 holding.
Mercer Global Advisors first reported a position in Niagen Bioscience in Q3 2023 and has held it in 9 quarters since.
Mercer Global Advisors's Niagen Bioscience position peaked at $299K in Q2 2025.
139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.